Paul J Pockros

Summary

Affiliation: Scripps Clinic
Country: USA

Publications

  1. ncbi request reprint Developments in the treatment of chronic hepatitis C
    Paul J Pockros
    Division of Gastroenterology HepatologyThe Scripps Clinic, 10666 N Torrey Pines Road, La Jolla, CA 92037, USA
    Expert Opin Investig Drugs 11:515-28. 2002
  2. ncbi request reprint The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients
    P J Pockros
    Department of Gastroenterology, Scripps Clinic, La Jolla, CA 92037, USA
    J Viral Hepat 10:55-60. 2003
  3. ncbi request reprint A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    Hepatology 37:1368-74. 2003
  4. ncbi request reprint Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy
    Paul J Pockros
    Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 40:1450-8. 2004
  5. ncbi request reprint Helminthic infections of the liver
    Paul J Pockros
    Division of Gastroenterology Hepatology, Liver Research Consortium, Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA
    Curr Gastroenterol Rep 6:287-96. 2004
  6. doi request reprint R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 48:385-97. 2008
  7. ncbi request reprint Antifibrotics for chronic hepatitis C
    Paul J Pockros
    Division of Gastroenterology and Hepatology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Clin Liver Dis 13:365-73. 2009
  8. ncbi request reprint Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 45:569-78. 2007
  9. ncbi request reprint Impact of obesity on treatment of chronic hepatitis C
    Michael R Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 43:1177-86. 2006
  10. ncbi request reprint Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 46:324-9. 2007

Detail Information

Publications37

  1. ncbi request reprint Developments in the treatment of chronic hepatitis C
    Paul J Pockros
    Division of Gastroenterology HepatologyThe Scripps Clinic, 10666 N Torrey Pines Road, La Jolla, CA 92037, USA
    Expert Opin Investig Drugs 11:515-28. 2002
    ....
  2. ncbi request reprint The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients
    P J Pockros
    Department of Gastroenterology, Scripps Clinic, La Jolla, CA 92037, USA
    J Viral Hepat 10:55-60. 2003
    ..These data suggest that CIFN may be safely combined with ribavirin and may enhance the sustained response rate but is not well tolerated in US patients when given in a daily dosing regimen...
  3. ncbi request reprint A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    Hepatology 37:1368-74. 2003
    ..In conclusion, IL-12 as monotherapy at the doses used in this trial for chronic hepatitis C has low efficacy, was poorly tolerated, and is unlikely to provide an alternative to conventional IFN-based therapy...
  4. ncbi request reprint Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy
    Paul J Pockros
    Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 40:1450-8. 2004
    ..Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy...
  5. ncbi request reprint Helminthic infections of the liver
    Paul J Pockros
    Division of Gastroenterology Hepatology, Liver Research Consortium, Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA
    Curr Gastroenterol Rep 6:287-96. 2004
    ..Current basic science and clinical research focus on improvements in medical therapy, mass screening and chemoprophylaxis, and the development of preventative vaccine strategies...
  6. doi request reprint R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 48:385-97. 2008
    ..Dosing of R1626 was limited by neutropenia; a study of different dosages of R1626 in combination with peginterferon alfa-2a and ribavirin is underway...
  7. ncbi request reprint Antifibrotics for chronic hepatitis C
    Paul J Pockros
    Division of Gastroenterology and Hepatology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Clin Liver Dis 13:365-73. 2009
    ..Progress on providing suitable end points to therapy will then promote the development of newer agents...
  8. ncbi request reprint Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 45:569-78. 2007
    ..IFN-gamma1b was well tolerated. There were similar numbers of deaths in all 3 arms (5, 5, and 4, respectively), and most were related to complications of cirrhosis...
  9. ncbi request reprint Impact of obesity on treatment of chronic hepatitis C
    Michael R Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 43:1177-86. 2006
    ....
  10. ncbi request reprint Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 46:324-9. 2007
    ..Longer studies to assess potential effects of IDN-6556 on liver inflammation and fibrosis are merited...
  11. ncbi request reprint Simeprevir for the treatment of chronic hepatitis C
    David M You
    Naval Medical Center San Diego, Division of Gastroenterology, Department of the Navy, CA, USA
    Expert Opin Pharmacother 14:2581-9. 2013
    ..Simeprevir (TMC435) is a second-generation protease inhibitor that is in development for the treatment of genotype 1 HCV infection...
  12. doi request reprint JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients
    Paul J Pockros
    Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA, USA
    Hepatology 58:514-23. 2013
    ..Conclusion: A 24-week response-guided combination regimen of mericitabine 1,000 mg BID plus Peg-IFNα-2a/RBV is well tolerated and more effective than a standard 48-week course of Peg-IFNα-2a/RBV...
  13. ncbi request reprint Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, California 92037, USA
    Am J Gastroenterol 99:1298-305. 2004
    ..This study compared the efficacy and safety of peginterferon alpha-2a 135 microg/wk, peginterferon alpha-2a 180 microg/wk and interferon alpha-2a in patients with chronic hepatitis C...
  14. ncbi request reprint Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 47:174-82. 2007
    ..To explore safety, pharmacokinetics, and pharmacodynamics of oral administration of resiquimod, a Toll-like receptor 7 and 8 agonist that induces endogenous interferon-alpha, in subjects with chronic hepatitis C virus infection...
  15. doi request reprint Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 52:1193-200. 2010
    ..0001). Conclusion: In patients with chronic hepatitis C who were treated with interferon-based therapies, histologic benefits may be observed even in the absence of an SVR...
  16. doi request reprint HCV RNA viral load assessments in the era of direct-acting antivirals
    Bryan Cobb
    Roche Molecular Systems Inc, Pleasanton, CA, USA
    Am J Gastroenterol 108:471-5. 2013
    ..This review summarizes terms used to report HCV RNA viral load results, explains the analytical performance of the PCR assay used in the clinical trials of boceprevir and telaprevir, and compares currently available commercial assays...
  17. doi request reprint Drugs in development for chronic hepatitis C: a promising future
    Paul J Pockros
    Division of Gastroenterology Hepatology and Liver Disease Center, The Scripps Translational Science Institute and The Scripps Research Institute, Scripps Clinic, La Jolla, CA 92037, USA
    Expert Opin Biol Ther 11:1611-22. 2011
    ..The approval of the first direct-acting antiviral (DAA) drugs for treatment of HCV in 2011 has lead to improved sustained viral response rates of up to 79% in treatment-naïve or relapse genotype 1 patients...
  18. ncbi request reprint The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
    Heather M Patton
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 40:484-90. 2004
    ..Questions remain regarding the etiology of steatosis in hepatitis C, and its impact on disease progression and treatment outcomes...
  19. ncbi request reprint SCV-07 (SciClone Pharmaceuticals/Verta)
    Richard J Aspinall
    Scripps Clinic, Division of Gastroenterology Hepatology, La Jolla, CA 92037, USA
    Curr Opin Investig Drugs 7:180-5. 2006
    ..Phase II clinical trials of the compound are ongoing...
  20. doi request reprint Nucleoside/nucleotide analogue polymerase inhibitors in development
    Paul J Pockros
    Division of Gastroenterology Hepatology, Liver Disease Center, Scripps Clinic, La Jolla, CA 92067, USA
    Clin Liver Dis 17:105-10. 2013
    ..Recent interim analyses indicate that many patients treated with only 2 direct-acting antiviral agents experience viral breakthrough, which can be significantly reduced by the addition of ribavirin without pegylated interferon α...
  21. doi request reprint Non-nucleoside analogue polymerase inhibitors in development
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Clin Liver Dis 17:123-8. 2013
    ..Several issues remain unclear at the time of this review; the role of these compounds including minimal dosing required, safety, and cost remains to be clarified...
  22. ncbi request reprint Interferon-free hepatitis C therapy: how close are we?
    Paul J Pockros
    Division of Gastroenterology Hepatology and Liver Disease Center, Scripps Clinic, The Scripps Translational Science Institute and The Scripps Research Institute, La Jolla, CA 92037, USA
    Drugs 72:1825-31. 2012
    ..These include lack of efficacy in certain populations, unexpected side effects, antiviral resistance, late relapse, lack of cooperation between drug developers and cost...
  23. doi request reprint New drugs for hepatitis C virus
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, The Scripps Research Institute, 10666 N Torrey Pines Road, La Jolla, CA 92037, USA
    Expert Rev Gastroenterol Hepatol 1:145-54. 2007
    ..The combination of direct antivirals, such as protease and polymerase inhibitors, may rapidly follow in development, as has occurred in HIV drug therapy...
  24. pmc A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels
    Richard J Aspinall
    Scripps Clinic, La Jolla, CA, USA
    Liver Int 31:1222-30. 2011
    ..We therefore examined whether a Src inhibitor could have therapeutic potential in ALF...
  25. pmc Comparison of esophageal capsule endoscopy and esophagogastroduodenoscopy for diagnosis of esophageal varices
    Catherine T Frenette
    Division of Gastroenterology and Hepatology, Scripps Clinic, San Francisco 94115, USA
    World J Gastroenterol 14:4480-5. 2008
    ..To investigate the utility of esophageal capsule endoscopy in the diagnosis and grading of esophageal varices...
  26. ncbi request reprint Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, California 92037, USA
    Am J Gastroenterol 97:2040-5. 2002
    ..Immune thrombocytopenic purpura (ITP) is an immune-mediated syndrome of unknown etiology characterized by the presence of autoantibodies against platelet membrane proteins...
  27. ncbi request reprint Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    ..Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C...
  28. ncbi request reprint Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Gastroenterology 126:1302-11. 2004
    ..This study assessed whether epoetin alfa could maintain RBV dose, improve quality of life (QOL), and increase hemoglobin (Hb) in anemic HCV-infected patients...
  29. ncbi request reprint Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data
    Calogero Cammà
    IBIM, Consiglio Nazionale delle Ricerche, Palermo, Italy
    Hepatology 39:333-42. 2004
    ..The beneficial effects of peginterferon on liver histology are closely related to virologic response...
  30. ncbi request reprint The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA
    Keyur Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
    Antivir Ther 10:535-41. 2005
    ..We compared the Catrimox-14 WB assay with a standard serum assay...
  31. ncbi request reprint Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C
    Keyur Patel
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Gastroenterol Hepatol 18:253-7. 2003
    ..However, its use in monitoring fibrosis over time has not been established. The aim of the present study was to assess the serial relationships between HA and liver fibrosis before and after treatment...
  32. doi request reprint Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin
    Michael W Fried
    University of North Carolina, Chapel Hill, NC 27514, USA
    Hepatology 48:1033-43. 2008
    ..The arm with the higher doses of both drugs was less well-tolerated than the other regimens...
  33. ncbi request reprint Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
    Samuel S Lee
    Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
    J Hepatol 37:500-6. 2002
    ..We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD)...
  34. ncbi request reprint Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life
    Sanjeev Arora
    Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    J Gastroenterol Hepatol 21:406-12. 2006
    ..HRQoL in the present population was also compared with HRQoL in patients with elevated ALT levels, observed in a previous study...
  35. ncbi request reprint Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
    Donald M Jensen
    Center for Liver Diseasees, University of Chicago Hospitals, 60637, USA
    Hepatology 43:954-60. 2006
    ..In conclusion, patients infected with HCV genotype 1 and treated with peginterferon alpha-2a/ribavirin sustained a RVR 24% of the time. This portends an 89% probability of a SVR after 24 weeks of treatment...
  36. doi request reprint Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Clichy, France
    Liver Int 28:477-85. 2008
    ..Pooled data from five studies of peginterferon alpha-2a in patients with chronic HCV infection (CHC) were compared with two studies of the drug in patients with chronic HBV infection (CHB)...
  37. ncbi request reprint Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis
    Zachary D Goodman
    Armed Forces Institute of Pathology, Division of Hepatic Pathology, Veterans Administration Special Reference Laboratory for Pathology, Washington, DC, USA
    Hepatology 45:886-94. 2007
    ....